In the past two weeks, the stock had slipped 26% from Rs 4,253 on November 5, after the company announced that it has received a warning letter from the US Food and Drug Administration ( US FDA) over quality control issues at three of its manufacturing facilities.
Warning letters are issued for violations of regulatory significance and these could lead to enforcement action such as import alerts, if not promptly and adequately corrected in voluntary compliance with the US drug laws by the companies.
Meanwhile, according to media reports, Lundin Law PC said it is investigating claims against Dr. Reddy’s Laboratories concerning possible violations of federal securities laws. The investigation is related to allegations that certain statements issued by Dr. Reddy’s were false and misleading concerning the company’s financial performance.
(CLICK HERE TO READ THE FULL REPORT)
The company has no further comment on what might be advertorial press releases by law firms and refutes all allegations, it added.
Sarabjit Kour Nangra, VP Research - Pharma, Angel Broking, said ‘currently we don’t think there are any major immediate financial implications of the same and hence, we maintain our numbers and BUY rating with a price target of Rs 3,933.
At 01:05 PM, the stock was down 1.4% at Rs 3,320, recovering nearly 6% from its early morning low on the NSE. The Nifty 50 was up 1.3% or 101 points at 7,833.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)